News & sentiment

ACURX PHARMACEUTICAL (ACXP) — News & AI sentiment

ACURX PHARMACEUTICAL (ACXP) news roundup. 1 story in the last 24 hours, 1 in the past week, 3 over 30 days. Average 24-hour sentiment is 67/100 — bullish-leaning (50 is neutral). No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →

24h stories

avg sentiment 67/100

7d stories

avg sentiment 67/100

30d stories

avg sentiment 60/100

Insider net (90d)

0 buys · 0 sells

Congress (90d)

0 buys · 0 sells

Latest stories on ACXP

FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection

PR Newswire67 · bullishproduct/pr

5h ago

Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection | ACXP Stock News

StockTitan63 · neutralproduct/pr

Jul 14

Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update

PR Newswire50 · neutralgeneral

Jul 8

Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference | ACXP Stock News

StockTitan56 · neutralproduct/pr

Jun 16

Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat

Morningstar73 · bullishgeneral

May 19

Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update

PR Newswire50 · neutralearnings

May 12

Open ACXP in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →